【Whether lung cancer patients should use immunotherapy after surgery, there is new evidence]
50-year-old Mr. Li is an executive of a foreign company. This year, he found a lung nodule in a routine physical examination. From the CT image, he was highly suspicious of a malignant nodule, so he went to the hospital as soon as possible. Hospitalized for radical surgery. Postoperative pathology showed adenocarcinoma, invading the pleura, with 20% micropapillary type and tumor thrombus in the vessels. A full set of genetic testing checks, no sensitive gene mutations. Judging from Mr. Li’s pathology, the stage is IB, and there are multiple high-risk factors for recurrence and metastasis, so postoperative adjuvant therapy is definitely required. But there is no gene mutation, and targeted drugs cannot be used. Can we only consider chemotherapy in the future? Should I add immunotherapy?
In the past, many clinicians have been entangled in the treatment of such patients. Although guidelines recommend adjuvant chemotherapy after surgery for stage IB lung cancer with high risk factors, in fact, chemotherapy can only reduce the Risk of recurrence, prolonging very limited survival. But there is no alternative to chemotherapy, because immunotherapy is only approved for patients with advanced lung cancer. Now, there is new and strong evidence on whether to join immunotherapy after early-stage lung cancer surgery.
